IP Library Granted Patent US 11,806,429
Granted Patent B2
US 11,806,429 · App. 17/579,914 · Granted Nov 7, 2023

Film formulations containing dexmedetomidine and methods of producing them

Inventors: Vasukumar Kakumanu (Guntur, IN); David Christian Hanley (Brookfield, CT); Frank Yocca (Clinton, CT); Chetan Dalpatbhai Lathia (Woodbridge, CT); Scott David Barnhart (Glen Rock, PA)
Assignee: BioXcel Therapeutics, Inc.
A61K9/0056A61K9/7007A61K31/4174A61K47/34A61K47/38A61P25/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,806,429
App. No.
17/579,914
Granted
Nov 7, 2023
Kind
B2
Abstract

Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.

Claims (15)

1. A method of treating agitation in a patient comprising administering a film comprising dexmedetomidine or a pharmaceutically acceptable salt thereof, water-soluble hydroxypropyl cellulose polymers having molecular weight of about 40,000 daltons, about 140,000 daltons, and about 370,000 daltons and a water-soluble polyethylene oxide polymer having a molecular weight of about 600,000 daltons, to the oral mucosa of the patient, wherein the method achieves about 70% to about 80% of C max within 2 hours of administration, wherein the C max is about 78 ng/L to about 200 ng/L, wherein said dexmedetomidine or pharmaceutically acceptable salt thereof is present in the film in an amount of about 40 micrograms.

2. The method of claim 1 , wherein the patient is a human.

3. The method of claim 1 , wherein the administration to the oral mucosa of the patient is sublingual administration.

4. The method of claim 1 , wherein the administration to the oral mucosa of the patient is buccal administration.

5. The method of claim 1 , wherein the C max is about 78 ng/L.

6. The method of claim 1 , wherein the C max is about 200 ng/L.

7. The method of claim 1 , wherein the C max is about 150 ng/L.

8. A film comprising dexmedetomidine or a pharmaceutically acceptable salt thereof, wherein the film achieves about 70% to about 80% of C max within 2 hours of administration, wherein the C max is about 78 ng/L to about 200 ng/L, wherein the dexmedetomidine or pharmaceutically acceptable salt thereof is present in an amount of about 40 micrograms, and wherein the film further comprises water-soluble hydroxypropyl cellulose polymers having molecular weight of about 40,000 daltons, about 140,000 daltons, and about 370,000 daltons and a water-soluble polyethylene oxide polymer having a molecular weight of about 600,000 daltons.

9. The film of claim 8 , wherein the C max is about 78 ng/L.

10. The film of claim 8 , wherein the C max is about 200 ng/L.

11. The film of claim 8 , wherein the C max is about 150 ng/L.

12. The film of claim 8 , wherein the film has a thickness of about 20 micrometers to about 200 micrometers.

13. The film of claim 8 , wherein the film has a thickness of about 20 micrometers to about 200 micrometers and covers an area (width×length) of about 100 mm 2 to about 300 mm 2 .

14. The film of claim 8 , wherein the film has a disintegration time of about 60 seconds to about 180 seconds.

15. The film of claim 8 , wherein the film is completely dissolvable in oral mucosal fluid in about 1 minute to about 5 minutes.

Assignments (8)
SECURITY INTEREST Recorded Sep 11, 2024
From: BIOXCEL THERAPEUTICS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 068938/0906 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2023
From: ARX, LLC
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 064538/0156 →
SECURITY INTEREST Recorded Apr 19, 2022
From: BIOXCEL THERAPEUTICS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 059726/0788 →
SECURITY INTEREST Recorded Apr 19, 2022
From: BIOXCEL THERAPEUTICS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 059727/0964 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2022
From: E. Z. BIOXCEL SOLUTIONS PVT. LTD.
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 058711/0772 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2022
From: BARNHART, SCOTT DAVID
To: ARX, LLC
Reel/Frame 058711/0943 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2022
From: KAKUMANU, VASUKUMAR
To: E.Z. BIOXCEL SOLUTIONS PVT. LTD.
Reel/Frame 058786/0542 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2022
From: HANLEY, DAVID CHRISTIAN; YOCCA, FRANK; LATHIA, CHETAN DALPATBHAI
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 058711/0548 →
Continuity (10)
Continuation 17103013 · Nov 24, 2020
Continuation 16931630 · Jul 17, 2020
Continuation 16453679 · Jun 26, 2019
Provisional Application 62849747 · May 17, 2019
Provisional Application 62798842 · Jan 30, 2019
Provisional Application 62787649 · Jan 2, 2019
Provisional Application 62767422 · Nov 14, 2018
Provisional Application 62693726 · Jul 3, 2018
Provisional Application 62690407 · Jun 27, 2018
Related Publication 20220142918A1 · May 12, 2022